Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

H. Zuo, P. M. Ueland, Midttun, G. S. Tell, A. Fanidi, W. Zheng, X. Shu, Y. Xiang, J. Wu, R. Prentice, M. Pettinger, C. A. Thomson, G. G. Giles, A. Hodge, Q. Cai, W. J. Blot, M. Johansson, J. Hultdin, K. Grankvist, V. L. StevensM. L. McCullough, S. J. Weinstein, D. Albanes, R. G. Ziegler, N. D. Freedman, N. E. Caporaso, A. Langhammer, K. Hveem, M. Næss, J. E. Buring, I. Lee, J. M. Gaziano, G. Severi, X. Zhang, M. J. Stampfer, J. Han, A. Zeleniuch-Jacquotte, L. L. Marchand, J. Yuan, R. Wang, W. Koh, Y. Gao, U. Ericson, K. Visvanathan, M. R. Jones, C. Relton, P. Brennan, M. Johansson, A. Ulvik

Research output: Contribution to journalArticle

Abstract

Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

Original languageEnglish (US)
Pages (from-to)478-485
Number of pages8
JournalAnnals of Oncology
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Vitamin B 6
Lung Neoplasms
Odds Ratio
Confidence Intervals
Pyridoxic Acid
Pyridoxal
Inflammation
Pyridoxal Phosphate
Logistic Models
Smoking
Prospective Studies

Keywords

  • inflammation
  • lung cancer
  • Lung Cancer Cohort Consortium
  • nested case-control study
  • PAr
  • vitamin B6

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Zuo, H., Ueland, P. M., Midttun, Tell, G. S., Fanidi, A., Zheng, W., ... Ulvik, A. (2019). Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3). Annals of Oncology, 30(3), 478-485. https://doi.org/10.1093/annonc/mdz002

Vitamin B6 catabolism and lung cancer risk : Results from the Lung Cancer Cohort Consortium (LC3). / Zuo, H.; Ueland, P. M.; Midttun; Tell, G. S.; Fanidi, A.; Zheng, W.; Shu, X.; Xiang, Y.; Wu, J.; Prentice, R.; Pettinger, M.; Thomson, C. A.; Giles, G. G.; Hodge, A.; Cai, Q.; Blot, W. J.; Johansson, M.; Hultdin, J.; Grankvist, K.; Stevens, V. L.; McCullough, M. L.; Weinstein, S. J.; Albanes, D.; Ziegler, R. G.; Freedman, N. D.; Caporaso, N. E.; Langhammer, A.; Hveem, K.; Næss, M.; Buring, J. E.; Lee, I.; Gaziano, J. M.; Severi, G.; Zhang, X.; Stampfer, M. J.; Han, J.; Zeleniuch-Jacquotte, A.; Marchand, L. L.; Yuan, J.; Wang, R.; Koh, W.; Gao, Y.; Ericson, U.; Visvanathan, K.; Jones, M. R.; Relton, C.; Brennan, P.; Johansson, M.; Ulvik, A.

In: Annals of Oncology, Vol. 30, No. 3, 01.03.2019, p. 478-485.

Research output: Contribution to journalArticle

Zuo, H, Ueland, PM, Midttun, Tell, GS, Fanidi, A, Zheng, W, Shu, X, Xiang, Y, Wu, J, Prentice, R, Pettinger, M, Thomson, CA, Giles, GG, Hodge, A, Cai, Q, Blot, WJ, Johansson, M, Hultdin, J, Grankvist, K, Stevens, VL, McCullough, ML, Weinstein, SJ, Albanes, D, Ziegler, RG, Freedman, ND, Caporaso, NE, Langhammer, A, Hveem, K, Næss, M, Buring, JE, Lee, I, Gaziano, JM, Severi, G, Zhang, X, Stampfer, MJ, Han, J, Zeleniuch-Jacquotte, A, Marchand, LL, Yuan, J, Wang, R, Koh, W, Gao, Y, Ericson, U, Visvanathan, K, Jones, MR, Relton, C, Brennan, P, Johansson, M & Ulvik, A 2019, 'Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)', Annals of Oncology, vol. 30, no. 3, pp. 478-485. https://doi.org/10.1093/annonc/mdz002
Zuo, H. ; Ueland, P. M. ; Midttun ; Tell, G. S. ; Fanidi, A. ; Zheng, W. ; Shu, X. ; Xiang, Y. ; Wu, J. ; Prentice, R. ; Pettinger, M. ; Thomson, C. A. ; Giles, G. G. ; Hodge, A. ; Cai, Q. ; Blot, W. J. ; Johansson, M. ; Hultdin, J. ; Grankvist, K. ; Stevens, V. L. ; McCullough, M. L. ; Weinstein, S. J. ; Albanes, D. ; Ziegler, R. G. ; Freedman, N. D. ; Caporaso, N. E. ; Langhammer, A. ; Hveem, K. ; Næss, M. ; Buring, J. E. ; Lee, I. ; Gaziano, J. M. ; Severi, G. ; Zhang, X. ; Stampfer, M. J. ; Han, J. ; Zeleniuch-Jacquotte, A. ; Marchand, L. L. ; Yuan, J. ; Wang, R. ; Koh, W. ; Gao, Y. ; Ericson, U. ; Visvanathan, K. ; Jones, M. R. ; Relton, C. ; Brennan, P. ; Johansson, M. ; Ulvik, A. / Vitamin B6 catabolism and lung cancer risk : Results from the Lung Cancer Cohort Consortium (LC3). In: Annals of Oncology. 2019 ; Vol. 30, No. 3. pp. 478-485.
@article{25cc1a6b407d4474a1e2750537c72c96,
title = "Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)",
abstract = "Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95{\%} confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95{\%} CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95{\%} CI: 1.36-2.10), men (OR: 1.60, 95{\%} CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95{\%} CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.",
keywords = "inflammation, lung cancer, Lung Cancer Cohort Consortium, nested case-control study, PAr, vitamin B6",
author = "H. Zuo and Ueland, {P. M.} and Midttun and Tell, {G. S.} and A. Fanidi and W. Zheng and X. Shu and Y. Xiang and J. Wu and R. Prentice and M. Pettinger and Thomson, {C. A.} and Giles, {G. G.} and A. Hodge and Q. Cai and Blot, {W. J.} and M. Johansson and J. Hultdin and K. Grankvist and Stevens, {V. L.} and McCullough, {M. L.} and Weinstein, {S. J.} and D. Albanes and Ziegler, {R. G.} and Freedman, {N. D.} and Caporaso, {N. E.} and A. Langhammer and K. Hveem and M. N{\ae}ss and Buring, {J. E.} and I. Lee and Gaziano, {J. M.} and G. Severi and X. Zhang and Stampfer, {M. J.} and J. Han and A. Zeleniuch-Jacquotte and Marchand, {L. L.} and J. Yuan and R. Wang and W. Koh and Y. Gao and U. Ericson and K. Visvanathan and Jones, {M. R.} and C. Relton and P. Brennan and M. Johansson and A. Ulvik",
year = "2019",
month = "3",
day = "1",
doi = "10.1093/annonc/mdz002",
language = "English (US)",
volume = "30",
pages = "478--485",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Vitamin B6 catabolism and lung cancer risk

T2 - Results from the Lung Cancer Cohort Consortium (LC3)

AU - Zuo, H.

AU - Ueland, P. M.

AU - Midttun,

AU - Tell, G. S.

AU - Fanidi, A.

AU - Zheng, W.

AU - Shu, X.

AU - Xiang, Y.

AU - Wu, J.

AU - Prentice, R.

AU - Pettinger, M.

AU - Thomson, C. A.

AU - Giles, G. G.

AU - Hodge, A.

AU - Cai, Q.

AU - Blot, W. J.

AU - Johansson, M.

AU - Hultdin, J.

AU - Grankvist, K.

AU - Stevens, V. L.

AU - McCullough, M. L.

AU - Weinstein, S. J.

AU - Albanes, D.

AU - Ziegler, R. G.

AU - Freedman, N. D.

AU - Caporaso, N. E.

AU - Langhammer, A.

AU - Hveem, K.

AU - Næss, M.

AU - Buring, J. E.

AU - Lee, I.

AU - Gaziano, J. M.

AU - Severi, G.

AU - Zhang, X.

AU - Stampfer, M. J.

AU - Han, J.

AU - Zeleniuch-Jacquotte, A.

AU - Marchand, L. L.

AU - Yuan, J.

AU - Wang, R.

AU - Koh, W.

AU - Gao, Y.

AU - Ericson, U.

AU - Visvanathan, K.

AU - Jones, M. R.

AU - Relton, C.

AU - Brennan, P.

AU - Johansson, M.

AU - Ulvik, A.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

AB - Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

KW - inflammation

KW - lung cancer

KW - Lung Cancer Cohort Consortium

KW - nested case-control study

KW - PAr

KW - vitamin B6

UR - http://www.scopus.com/inward/record.url?scp=85064129265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064129265&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz002

DO - 10.1093/annonc/mdz002

M3 - Article

C2 - 30698666

AN - SCOPUS:85064129265

VL - 30

SP - 478

EP - 485

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -